Recently, a drug shown to modestly slow the early stages of Alzheimer's was approved by FDA. The drug continues to be studied in larger and longer trials.
CLEVELAND — Recently, a drug shown to modestly slow the early stages of Alzheimer's was approved by the Food and Drug Administration. The move allows for earlier approval of medication while the drug continues to be studied in larger and longer trials.
According to a Bloomberg analysis last year, only about 2% of overall Alzheimer's clinical trial participants were Black. Older Black Americans are twice as likely as white Americans to have Alzheimer's or other forms of dementia. The program, called the Ahead Study, will last about four years. Results are expected around the year 2028.RELATED: Cleveland Clinic seeks diverse participants in clinical trials for Alzheimer's treatmentLeqembi, known chemically as lecanemab, is the first drug that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
7th dead whale to wash ashore recently likely struck by a vessel, examination showsThe 32-foot female had injuries to her head, spine and right side and flipper.
Les mer »
Al Brown, 'The Wire' Star, Dead at 83Al Brown, known for his work on the hit HBO series 'The Wire' as Col. Stan Valchek, has died at 83.
Les mer »
‘The Wire’ Star Dies After Battle With Alzheimer’s DiseaseAl Brown had a long list of credits to his name but is most remembered for his time on the hit TV series.
Les mer »
Eisai files for approval of Alzheimer's drug in JapanJapanese drugmaker Eisai Co Ltd said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States.
Les mer »
Alzheimer’s drug saga prompts journal to scrutinize whistle-blowersPublication requires complainants to disclose financial conflicts in the wake of controversy over Cassava Sciences’ experimental treatment simufilam.
Les mer »
U.S. FDA, CDC see early signal of possible Pfizer bivalent COVID shot link to strokeA safety monitoring system flagged that U.S. drugmaker Pfizer Inc and German partner BioNTech's updated COVID-19 shot could be linked to a type of brain stroke in older adults, according to preliminary data analyzed by U.S. health authorities.
Les mer »